Piper Sandler Issues Positive Forecast for Mesoblast (NASDAQ:MESO) Stock Price

Mesoblast (NASDAQ:MESO) had its price objective boosted by Piper Sandler from $11.00 to $15.00 in a research report report published on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

Other equities analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Mesoblast from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Jefferies Financial Group raised Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday, August 29th. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Tuesday, September 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research note on Thursday, August 29th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Mesoblast currently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Mesoblast Trading Down 12.4 %

MESO traded down $2.07 during trading on Thursday, hitting $14.69. The company’s stock had a trading volume of 112,482 shares, compared to its average volume of 733,866. Mesoblast has a one year low of $1.61 and a one year high of $19.15. The business’s 50 day simple moving average is $10.39 and its 200-day simple moving average is $8.23. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.

Institutional Trading of Mesoblast

A number of hedge funds have recently bought and sold shares of MESO. Perkins Coie Trust Co lifted its stake in shares of Mesoblast by 15.0% during the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after purchasing an additional 1,500 shares during the last quarter. Signaturefd LLC increased its stake in shares of Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after acquiring an additional 3,099 shares during the period. Lazari Capital Management Inc. raised its holdings in shares of Mesoblast by 6.6% during the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after purchasing an additional 3,300 shares during the last quarter. Pine Valley Investments Ltd Liability Co purchased a new stake in Mesoblast in the second quarter valued at $80,000. Finally, Rathbones Group PLC acquired a new stake in Mesoblast during the 2nd quarter worth about $95,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.